ClinicalTrials.gg
Active, not recruitingNCT07226258Updated Oct 20, 2026

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

A Phase 3 interventional study of SL1002 and Normal Saline in Osteoarthritis Knee Pain, sponsored by Saol Therapeutics Inc. Active, not recruiting at 22 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Saol Therapeutics Inc · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
204th of 691
150 · median 72
Started
2025
with 36 others
Phase 3
76 of 796
6 open now
Primary completion
2026-11
later than 40 of 152 live
Registered
769th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 204th largest by planned enrollment of the 691 interventional ones that give a count, is one of 37 that started in 2025, is one of 76 in phase 3, reaches primary completion later than 40 of the 152 other live ones, and was the 769th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single treatment of SL1002 compared to placebo for the treatment of knee pain associated with mild to moderate osteoarthritis.

03

Conditions studied

  • Osteoarthritis Knee Pain
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 40 years of age
  2. (BMI) limits
  3. Chronic knee pain resulting from osteoarthritis
  4. Kellgren-Lawrence Grade 2 (mild) or Grade 3 (moderate)
  5. Baseline KOOS pain
  6. Patients taking baseline analgesics
  7. Diagnostic nerve block response
  8. Compliance with identified study requirements

Exclusion criteria

Exclusion Criteria includes:

  1. Non-OA inflammatory arthritis
  2. Confounding elements
  3. Lower limb amputation.
  4. Specified alternate historic treatments
  5. Identified underlying physiologic or psychosocial conditions
  6. Patient Health Questionnaire
  7. Moderate to severe hepatic impairment
  8. Moderate to severe renal impairment
  9. Identifiable baseline medications
  10. Protocol compliance requirements
  11. Known allergies or to identified agents
  12. Identified alcohol or drug abuse history
  13. Identified underlying physical exam findings: abnormalities or vital sign abnormalities during study screening per investigator assessment
  14. Identified underlying abnormal laboratory results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    SL1002

    SL1002

    Drug: SL1002

  • Placebo comparator
    Placebo

    Normal saline

    Drug: Normal Saline

Interventions

  • DrugSL1002

    SL1002 injectable solution

  • DrugNormal Saline

    Normal Saline

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Weekly Mean of the Average Daily Pain Intensity While Walking

    The pain intensity score is measured using a numeric rating scale (NRS)

    Time frame: Baseline to week 12

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 12 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Feb 28, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226258
Lead sponsor
Saol Therapeutics Inc
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 7, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SL1002

Start the discussion